Despite a tumultuous period,
Salesforce (CRM) is still gathering interest from investors, analysts, and asset managers across the globe. Recently they announced a
$25 billion accelerated share repurchase and an ambitious long-term strategy through to FY27, although top-level employees will not see raises this year. The company's share price has
declined 35% over the past year, with its value having dipped by 30% specifically. Despite this, some investors claim the stock is at a doomsday valuation, suggesting they see a recovery on the horizon.
BNP Paribas expects catalysts to turn the stock around after updating their price target from $220 to $230. This follows stock purchases from insiders and Salesforce's application of AI within government healthcare and its other workflows. However, possible risks are arising around the complexity of Salesforce's metadata. Bearish signals persist, but the company recently won a $5.6bn contract with the US Army and is continuing to invest in AI, suggesting a positive future. Lastly, Salesforce's Agentforce is delving deeper into AI and customer service, possibly signalling its greatest opportunity despite market jitters.
Salesforce CRM News Analytics from Mon, 01 Dec 2025 08:00:00 GMT to Sat, 28 Mar 2026 20:24:59 GMT -
Rating 1
- Innovation 5
- Information 7
- Rumor -4
